103
Participants
Start Date
September 30, 2006
Primary Completion Date
April 30, 2009
Study Completion Date
April 30, 2009
Avastin (Bevacizumab)
Avastin 1.25 mg intravitreal
Bevacizumab
Intravitreal 1.25 mg
Bevacizumab
Intravitreal 1.25 mg
Bevacizumab
Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
The University of Alberta and Capital Health, Edmonton
The University of British Columbia, Vancouver
Dr. Stanley G. Shortt, Victoria
Ivey Eye Institute, St. Joseph's Health Care Centre, London
Sunnybrook Health Sciences Centre, Toronto
QLT Inc.
INDUSTRY
Canadian Retinal Trials Group
OTHER
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER